Skip to main content
KAZIA THERAPEUTICS LTD logo

KAZIA THERAPEUTICS LTD — Investor Relations & Filings

Ticker · KZIA ISIN · US48669G1058 US Professional, scientific and technical activities
Open in API
Filings indexed 1,045 across all filing types
Latest filing 2025-01-30 Regulatory Filings
Country US United States of America
Listing US KZIA

About KAZIA THERAPEUTICS LTD

https://www.kaziatherapeutics.com/

Kazia Therapeutics Ltd. is an oncology-focused biotechnology company engaged in the development of innovative drugs for cancer. The company's lead program is paxalisib, a small molecule inhibitor of the PI3K/AKT/mTOR pathway designed to cross the blood-brain barrier, which is being investigated for various forms of brain cancer. Its development pipeline also includes EVT801, a selective VEGFR3 inhibitor being studied for its potential to block the growth of blood and lymphatic vessels that support tumor growth. The company focuses on addressing cancers with high unmet medical needs through its portfolio of targeted therapies.

Recent filings

Filing Released Lang Actions
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Kazia Therapeutics Limited, with the SEC. It contains a press release about the launch of a clinical trial and references the press release as Exhibit 99.1. The document is short (2178 characters) and primarily serves to report current company news rather than provide detailed financial data or comprehensive reports. Form 6-K filings are typically used for current reports by foreign private issuers and do not constitute full annual or quarterly reports. The content is a regulatory announcement of a press release rather than a full financial or management report. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-01-30 English
Regulatory Filings 2025
Regulatory Filings
2025-01-17 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-01-16 English
424B3
Capital/Financing Update Classification · 100% confidence The document is a Form 6-K filed by Kazia Therapeutics Limited, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content primarily details a securities purchase agreement, a registered direct offering, a private placement, and related financing activities including warrants and placement agent agreements. It includes detailed terms of the offering, use of proceeds, and legal opinions related to the offering. The document is not an annual or interim report, audit report, earnings release, or any other type of report but rather an update on capital raising activities. The presence of terms like 'securities purchase agreement', 'registered direct offering', 'private placement', 'placement agent agreement', and detailed descriptions of the offering structure clearly indicate this is a Capital/Financing Update. The document length is substantial and contains substantive details about the financing transaction, not merely an announcement or a brief summary. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2025-01-13 English
424B3
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Kazia Therapeutics Limited, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content details a securities purchase agreement, registered direct offering, private placement, placement agency agreement, and related legal opinions and exhibits. It includes information about the offering of American Depositary Shares (ADSs), warrants, and related terms. The document is a regulatory filing providing updates on capital raising activities and related agreements, not a full financial report or earnings release. It is not an annual or interim report, nor a proxy or voting result announcement. The document is a detailed regulatory filing about financing activities and related legal documentation, consistent with the definition of a Regulatory Filing (RNS).
2025-01-13 English
6-K
Capital/Financing Update Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Kazia Therapeutics Limited, with the SEC. It details a concurrent registered direct offering and private placement, including terms of securities purchase agreements, warrants, placement agency agreements, and lock-up agreements. The document includes legal opinions and exhibits related to the offering. It is a regulatory filing reporting a capital raising event and related agreements, not a full financial report or earnings release. The document length is about 14,198 characters, which is substantive but the content is focused on financing activities and related legal documentation. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2025-01-13 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.